The foundation of our corporate culture
is the awareness of the social value of plasma
processing for the treatment of extremely
severe and debilitating diseases, such as
haemophilia and immune deficiencies.

We invest in people, innovation and research to
support the medical and scientific communities
and the institutional patient communities
worldwide, for ongoing product and
process improvement, to give our contribution
to making treatments widely available

NEW » KEDRION RECEIVES QSEAL CERTIFICATION FROM PPTA
08/02/2010

NEWS:
GROWTH OF THE KEDRION GROUP: EXPANSION OF THE HUNGARIAN PLANT STARTING NOW. A NEW PLASMAPHERESIS CENTRE SETTLED IN BUDAPEST
02/12/2009

NEWS:
HAEMOPHILIA: KEDRION WINS AWARD IN INDIA
09/01/2009